Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2009. For the third quarter of 2009, the Company reported a net loss of $8.2 million, or $0.21 per share, compared with a net loss of $17.7 million, or $0.46 per share, for the same period in 2008. For the nine months ended September 30, 2009, the Company reported a net loss of $43.1 million, or $1.11 per share, as compared to $59.8 million, or $1.56 per share, for the same period last year.

Revenues for the third quarter of 2009 were $0.7 million, compared with $0.8 million for the same period last year. Revenues for the nine months ended September 30, 2009 were $2.2 million, compared with $3.2 million for the same period in 2008. The decrease in revenues is primarily due to milestones recognized in 2008 under our collaboration agreement with GlaxoSmithKline related to the clinical advancements of our CRF program. During both nine month periods ending September 30, 2009 and 2008, we recognized $2.2 million in revenue under our collaboration agreement for indiplon with Dainippon Sumitomo Pharma Co. Ltd. from amortization of up-front licensing fees.

Research and development expenses decreased to $7.4 million during the third quarter of 2009 compared with $13.0 million for the same period in 2008. For the nine months ended September 30, 2009, research and development expenses were $29.1 million, compared to $43.4 million for the same period last year. The decrease in research and development expenses is primarily due to cost savings from our recent restructuring and decreasing external clinical development expenses related to the elagolix program. Personnel costs decreased in the first nine months of 2009 by $3.0 million compared with the first nine months of 2008 and
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  BioLife Solutions, Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues ("BioLife" or the "Company"), announced that the ... Conference. The Company is scheduled to present ... 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, ... announced a peer-reviewed publication of the results of ... RGN-259 (RegeneRx,s preservative-free eye drops) for the treatment ... adverse environment (CAE ® ) model.  The exploratory ... results, which were previously disseminated by the Company ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... Henry Schein, Inc. (Nasdaq: HSIC ), the ... practitioners, announced today that it will release its third quarter ... October 29, 2010, and will provide a live webcast of ... 10:00 a.m. Eastern Daylight Time. Speakers on the call will ...
... French genome engineering specialist, today published its consolidated financial ... increased 25% over H1 2009, expenditure increased 50% and ... in cash reserves. During the first half ... new agreements (with BASF Plant Science, Boehringer Ingelheim), published ...
Cached Medicine Technology:Henry Schein to Webcast Third Quarter 2010 Conference Call Friday, October 29, at 10:00 a.m. EDT 2Cellectis Publishes Its Financial Statement for the First Half of 2010 2Cellectis Publishes Its Financial Statement for the First Half of 2010 3
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ProFlare ... simple as dragging and dropping footage into the FCPX timeline ... , Including over 80 stunning flares, ProFlare 5K Prism ... the ultimate bundle for adding prismatic refractions to any video. ... movie files designed for Final Cut Pro X, but are ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood ... designing with reclaimed wood, introducing their latest reclaimed wood ... Their newest offerings, Vat 35, Reclaimed Teak , ... to America's largest design event. , “Designers, architects, builders, ... anxious to see and feel the variety of wood ...
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... May 22, 2015 Omar Ahmad Barrada, ... to participate in the 2015 Congress of Future Medical ... as a gathering of “America’s highest achieving high school ... of healthcare, set new goals and learn better study ... live surgery, during which we can ask the surgeons ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... for its treatment by the FDA, following a clinical ... Taxotere survived an average of 11.4 months without disease ... ,The drug will be used before radiation, ... advanced squamous cell head and neck cancer. Its side ...
... human gene therapy for Parkinson's disease has given the green ... reducing symptoms for patients,// according to the reports of two ... yesterday and last week the researchers reported that each of ... trials received some benefit and none had significant side effects. ...
... A new experimental vaccine developed by scientists in the US ... help prevent the disease that has kills one million// people ... S and developed by Walter Reed Army Institute of Research ... percent for up to 18 months after vaccination among children ...
... a computer-driven system can significantly reduce the duration ... the intensive// care unit (ICU), as compared with ... ,The study, which was conducted in five medical-surgical ... appears in the second issue for October 2006 ...
... in the October issue of the Journal of the American ... elderly women who have not received// up to the mark ... compared to the younger lot. , ,David Litvak ... colleagues studied the records of 354 breast cancer patients who ...
... turning out to be a big challenge for law enforcement officials ... from the last decade, lock-ups /arrests due to possession of ice ... ,Yet, despite this entire hullabaloo, scientists have not been able ... that is still unclear about the link between this drug and ...
Cached Medicine News:Health News:Gene therapy Beneficial in Parkinson's Disease 2Health News:Gene therapy Beneficial in Parkinson's Disease 3Health News:Computer-Driven System Reduces Patient Mechanical Ventilation Time Significantly 2
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... complete line of flowmeters, available in ... . They are all available in ... suit your application. With color coded ... gas in use, the Amvex Flowmeter ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line of ... and CO 2 . They are ... calibrations to best suit your application. ... specific to the gas in use, ...
Medicine Products: